340B项目在2025年的规模与增长：预估340B采购总额达180-200亿美元（按标价计算）

The Size and Growth of the340B Program in 2025 Estimated 340B purchases totaled $180-$200 billion at list prices RORY MARTIN,PhD, IQVIA Market Access Technology SolutionsHARISH KARNE,MS, IQVIA Market Access Technology SolutionsSHANYUE ZENG,MS, IQVIA Market Access Technology Solutions Table of contents AbstractIntroductionFindings The hospital and clinic channels now account for almostthree quarters of 340B purchases; and five disease areas— targeted oncology, immunology, anti-virals, diabetes, Abstract This study is part of an ongoing series by IQVIA thatexamines the size and growth of the 340B drug pricingprogram, and provides a descriptive estimate of the size, The future growth of the 340B program may beinfluenced by additional states enacting contractpharmacy mandates and ambiguity in how some 340Bproviders interpret patient eligibility rules. In addition, In 2025, 340B purchases reached $179.5 billion at listprices, growing 20.3% year-over-year. From 2018 to 2025,340B purchases at list prices more than tripled in sizeand grew at three times the rate of the rest of the U.S. consolidation due to practice acquisition,2growth ofcontract pharmacy networks including the establishmentof in-house specialty pharmacies, a higher propensity for340B providers to treat patients using drugs versus their Introduction The 340B drug pricing program (“340B program”)is a federal program in which drugmakers providesubstantial, medicaid-like discounts on qualifying drugs Program growth has also been driven by policy changes,including 340B providers being able to use an unlimitednumber of contract pharmacies, and the introduction by The substantial and sustained growth of the programinrecent years has led to an intense debate about growthdrivers, and whether growth is being driven by increasedutilization or drug price increases. A recent study published The current study provides an estimate of the 340Bprogram’s size and growth for 2025, including breakouts Findings In 2025, 340B purchases at list prices reached $179.5 billion, as shown in Figure 1. From January 2018 throughDecember 2025, 340B purchases grew 232.8%, versus 71.3% for non-340B purchases, as shown in Figure 2, meaning pharmacy chains, independent pharmacies, and mailorder pharmacies. 340B sales through the retail andmail channels were $41 billion. Conversely, for non-340Bdrugs, only 28% of purchases involved the hospital and Channel trends In 2025, almost three quarters of 340B purchases werein the hospital and clinic channels, representing self-administered drugs dispensed at hospital and clinicoutpatient pharmacies as well as physician-administered 2018 is shown in figure 4. Over this period immunologydrugs had the highest indexed growth of 645.3% for340B purchases, versus 273.6% for non-340B purchases,illustrating the rapid growth of this segment during this Disease areas Five disease areas accounted for 67.6% of 340Bpurchases at list prices, which were, in descending order,targeted oncology, immunology, anti-virals, diabetes, which, if implemented, would likely grow the programby tens of billions of dollars. Also, ongoing litigation andregulatory ambiguity regarding the 340B patient definition Discussion In 2025, 21 states enacted contract pharmacy mandatepolicies, requiring drugmakers to honor 340B pricingwhen 340B-eligible drugs are dispensed using contractpharmacies, bringing the total number of states with suchmandates to 32. Also, 340B purchases at list price in 2025grew 20.3%, the highest rate observed since 2020, the yearbefore the majority of manufacturers’ contract pharmacy Conversely, a handful of factors may slow program growth.For example, on January 1, 2026, the first 10 drugs subjectto price negotiation began reimbursing dispensing entitiesat Maximum Fair Price (MFP). Furthermore, 5 of these 10drugs substantially decreased their list prices, which will, Although the subnational sales data used for this study isa national sample, it does not capture 100% of drug sales,and we did not attempt to project the sample size to 100%. Another factor that may slow program growth is the use ofa 340B rebate model. The rebate model pilot program thatwas supposed to begin on January 1, 2026 was enjoinedby the courts in December 2025, and at the time of The future growth trajectory of the 340B program isuncertain and will be influenced by multiple factors. Forexample, eight states have introduced but not yet fully and rheumatoid arthritis), anti-virals (e.g., drugs for HIVand HEP-C), respiratory therapy (drugs for asthma andCOPD), hemostatic agents (such as heparins and anti-coagulants), psychotherapeutics (antipsychotics, anti-depressants, and ADHD products), neurological agents Data sources Purchasing (sales) data were sourced from IQVIA’s DDDsubnational sales database from 2018 to 2025. Dataincluded all disease areas, specialty and non-specialtyproducts, branded drugs and generics, prescription and Distribution channels a